ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 130 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $84,000 | -61.8% | 1,000 | -56.5% | 0.00% | -66.7% |
| Q1 2019 | $220,000 | -36.6% | 2,300 | -53.1% | 0.01% | -42.9% |
| Q4 2018 | $347,000 | -20.4% | 4,900 | -3.9% | 0.02% | -4.5% |
| Q3 2018 | $436,000 | -30.4% | 5,100 | -5.6% | 0.02% | -33.3% |
| Q2 2018 | $626,000 | -28.4% | 5,400 | -50.0% | 0.03% | -31.2% |
| Q1 2018 | $874,000 | +37.9% | 10,800 | 0.0% | 0.05% | +41.2% |
| Q4 2017 | $634,000 | -32.3% | 10,800 | -46.0% | 0.03% | -33.3% |
| Q3 2017 | $936,000 | +25.6% | 20,000 | -3.4% | 0.05% | +21.4% |
| Q2 2017 | $745,000 | -1.3% | 20,700 | -15.5% | 0.04% | -2.3% |
| Q1 2017 | $755,000 | -5.3% | 24,500 | +2.9% | 0.04% | -12.2% |
| Q4 2016 | $797,000 | +310.8% | 23,800 | +170.5% | 0.05% | +276.9% |
| Q3 2016 | $194,000 | 0.0% | 8,800 | 0.0% | 0.01% | 0.0% |
| Q2 2016 | $194,000 | – | 8,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
| Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
| Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
| Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
| Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
| ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
| Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
| Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |